Please Wait
Applying Filters...
menu
    • menu

    List of Drug Master Files (DMF) of 4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate Active Pharmaceutical Ingredient (API) submitted to the U.S. FDA. Original Data : FDA Website

    Client Email Product
    2024 US Elections: Harris, Trump differ on abortion rights, ACA, public health spends; agree on need to cut drug prices

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 653Xls download

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Holder DMF No. Subject Submission Date Status Type GDUFA DMF Review GDUFA Review Date GDUFA Payment Date
    26/09/2024 Actavis Inc
    Ireland
    		 TEVA PHARMACEUTICAL INDUSTRIES LTD 26077 OXYBUTYNIN BASE 2012-06-13 Active II N/A
    26/09/2024 Juzen Chemical Corporation
    Japan
    		 JUZEN CHEMICAL CORP 14071 OXYBUTYNIN 1999-03-30 Inactive II N/A